Clinical Trials · NCT00171730

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

Name: An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Octreotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Novartis Pharmaceuticals
Enrollment: 30
Start date: Aug 2004
Locations: 10 sites, 7 countries
Primary endpoint: Percentage of Participants With Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) Observed Response by Dose Class

View Octreotide compound reference